GlassScriptPhysician profile
Yasir Ahmed
NPI 1982968319
$10,236.65
in general payments reported to CMS, 2019-2025
25 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $334 · 2021: $1,431 · 2022: $1,854 · 2023: $1,800 · 2024: $2,521 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,311.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,829.10 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Alcon Vision LLC | $1,528.97 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Glaukos Corporation | $1,409.76 | 2020-2025 | Photrexa Viscous and Photrexa, Idosetr, Photrexa |
| Biotissue Holdings INC. | $858.23 | 2019-2025 | |
| Allergan, INC. | $780.09 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $658.39 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $532.37 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $462.54 | 2019-2023 | |
| Harrow Eye, LLC | $401.61 | 2024-2025 | Vevye, Iheezo |
| Oyster Point Pharma, INC. | $345.63 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $290.50 | 2020-2023 | Flarex |
| Dompe US, INC. | $247.70 | 2019-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $184.29 | 2023 | Acthar |
| Aerie Pharmaceuticals, INC. | $155.62 | 2021 | |
| Rxsight INC | $132.08 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $101.84 | 2022-2023 | Quatera 700 |
| Sight Sciences, INC. | $83.41 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.53 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $36.14 | 2019-2020 | |
| Ocular Therapeutix, INC. | $31.76 | 2022-2023 | Dextenza |
| E.R. Squibb & Sons, L.L.C. | $26.19 | 2025 | Camzyos |
| Johnson & Johnson Surgical Vision, INC. | $25.10 | 2019 | |
| Thea Pharma INC. | $23.02 | 2023 | |
| Amgen INC. | $15.91 | 2025 | Tepezza |
| Akorn Operating Company LLC | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasir Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.